These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16098458)

  • 1. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
    Zalcberg JR; Verweij J; Casali PG; Le Cesne A; Reichardt P; Blay JY; Schlemmer M; Van Glabbeke M; Brown M; Judson IR; ;
    Eur J Cancer; 2005 Aug; 41(12):1751-7. PubMed ID: 16098458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
    Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
    J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy].
    Wang CM; Shi YQ; Ye YW; Fu H; Zhao GF; Zhou Y; DU CY; Dong RZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Mar; 12(2):155-8. PubMed ID: 19296251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
    Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
    Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
    Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib and inoperable or metastatic gastrointestinal stromal tumours. Longer follow-up confirms the overall survival benefit.
    Prescrire Int; 2011 Mar; 20(114):61-3. PubMed ID: 21648223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Cohen MH; Farrell A; Justice R; Pazdur R
    Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
    Judson I
    Curr Opin Oncol; 2008 Jul; 20(4):433-7. PubMed ID: 18525340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.
    Patel S; Zalcberg JR
    Eur J Cancer; 2008 Mar; 44(4):501-9. PubMed ID: 18234488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
    Sciot R; Debiec-Rychter M; Daugaard S; Fisher C; Collin F; van Glabbeke M; Verweij J; Blay JY; Hogendoorn PC; ; ;
    Eur J Cancer; 2008 Sep; 44(13):1855-60. PubMed ID: 18653326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
    J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
    Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
    Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
    Van Glabbeke M; Verweij J; Casali PG; Simes J; Le Cesne A; Reichardt P; Issels R; Judson IR; van Oosterom AT; Blay JY
    Eur J Cancer; 2006 Sep; 42(14):2277-85. PubMed ID: 16876399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
    Verweij J; Casali PG; Kotasek D; Le Cesne A; Reichard P; Judson IR; Issels R; van Oosterom AT; Van Glabbeke M; Blay JY
    Eur J Cancer; 2007 Apr; 43(6):974-8. PubMed ID: 17336514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.